Revvity's EUROIMMUN Launches APOE Genotyping Assay for Alzheimer's Therapy Risk Assessment

• Revvity's EUROIMMUN has launched the EURORealTime™ APOE assay for accurate APOE genotyping in European countries, aiding in assessing ARIA risk before anti-amyloid therapy.
• The EURORealTime APOE PCR test simultaneously detects APOE forms E2, E3, and E4, with E4 carriers exhibiting the highest risk for ARIA during Alzheimer's treatment.
• The assay uses genomic DNA from a single blood sample and can be automated on Revvity instruments, streamlining APOE genotype determination for personalized treatment.
• This new APOE genotyping approach provides clinicians with additional patient information, enabling a more personalized strategy for anti-amyloid (beta) treatment in Alzheimer's patients.

Revvity, Inc., has announced the release of the EURORealTime™ APOE assay by its EUROIMMUN business in European countries accepting the CE mark. This in-vitro diagnostic tool facilitates precise APOE genotyping, crucial for evaluating a patient's susceptibility to adverse effects before initiating anti-amyloid (beta) therapy for Alzheimer’s disease.

Significance of APOE Genotyping

According to Dr. Lars Komorowski, Chief Scientific Officer at EUROIMMUN, the advent of disease-modifying drugs marks a new era in Alzheimer's treatment. However, patients with specific APOE gene variants face a heightened risk of developing potentially life-threatening side effects, known as ARIA (amyloid-related imaging abnormalities), characterized by edema or microbleeds in the brain. Determining a patient's APOE genotype prior to therapy is therefore essential for assessing individual risk.

EURORealTime APOE PCR Test Details

The EURORealTime APOE PCR test enables the simultaneous detection of the three most common APOE variants: E2, E3, and E4. Individuals carrying exclusively the E4 variant are at the greatest risk of ARIA during treatment. Revvity’s new test requires only a single reaction using genomic DNA extracted from a blood sample to ascertain a patient's APOE genotype. The assay can be automated on Revvity platforms, including the EUROIMMUN PreNAT II™ and the chemagic™ 360, with results analyzed, documented, and archived using the EURORealTime analysis software.

Clinical Implications

For clinicians managing Alzheimer’s patients, this APOE genotyping method offers valuable patient-specific data, facilitating a more tailored approach to anti-amyloid (beta) treatment. By identifying patients at higher risk for ARIA, clinicians can make informed decisions about treatment strategies, potentially mitigating severe side effects and improving patient outcomes.